News and Announcements
Wonder of Human Flight Comes to Australia
- Published October 12, 2012 1:31PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Australian thrill seekers as young as 5 years old will soon be able to experience the wonder of flight – without parachutes – at a new entertainment facility planned for Western Sydney.
Indoor Skydive Australia Group’s corporate team is made up with experienced professionals and the company is first to obtain approvals to build the latest generation tunnel in Australia, located at the soon to be redeveloped Penrith Leagues Club with a target of completion by January 2014.
Danny Hogan, Chief Operations Officer of Indoor Skydive Australia Group, says that over 23 such facilities already exist around the world, based on technology originally pioneered in Australia.
“This is sixth generation technology which has evolved from an idea tried on the Sunshine Coast in Queensland in the 1980s,” he says.
“Basically, air from electric fans is passed through a flight chamber to create lift, and allows people to safely experience the joy of flight.”
The Penrith facility is the same technology as the most recent implementation, which is successfully operating on Singapore’s Sentosa island. Other facilities are operational throughout Europe and the United States, where former President George W Bush tried the experience.
Danny Hogan says the Penrith project is one of the cornerstones of the proposed $850 million leisure and lifestyle precinct destined for Penrith Leagues Club, which is also located close to the planned $150 million Wet n’Wild park.
The ISA Group will be conducting a public offer in November this year where they will be offering between 8 – 10 million dollars in shares. The group plans to build a portfolio of facilities across Australia and the region.
To know more about Indoor Skydive Australia Group, please click here.
For full details of the offer, download a prospectus or to register for an event please visit our website http://www.indoorskydiveaustralia.com.au or follow the link to our online application form at http://www.boardroomlimited.com.au/isagroupoffer
Company Updates
Arterial Alchemy: Turning the ‘Ticking Time Bomb’ of Heart Disease into Excretable Waste
Current heart medications thin the “grease” in our blood, but Atherid Therapeutics is building the first biological clearing agent to actually scrub the pipes clean. With human trials slated for 2027, the goal is to make heart attacks a preventable and reversible condition.
Breaking the ‘Bird’s Nest’: How Amplia Therapeutics is Piercing the Shield of Pancreatic Cancer
Led by award-winning drug developer Dr. Chris Burns, Amplia Therapeutics (ASX: ATX) is taking a “one-two punch” approach to one of medicine’s deadliest challenges. By utilizing their lead asset, narmafotinib, to dismantle the protective “bird’s nest” of fibrotic tissue surrounding pancreatic tumors, Amplia has achieved a 35% interim response rate in Phase 2a trials. With FDA Fast Track status and critical survival data expected in 2026, the company is rapidly approaching a major commercial and clinical rerate.
The Australian Life Science Sector: A Structural Convergence of 5 Critical Factors
For a decade, we have watched the foundation being built. Government grants are flowing into research infrastructure. Labs constructed. IP portfolios are growing. Talent returning from global pharma. For most of that decade, the returns were slow, the timelines were long, and the capital was cautious. That era is over. The Australian life science sector […]
Backed By Leading Investment Groups and Family Offices
